Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ZymoGenetics begins phase III surgial hemostat trial
The study will compare the efficacy of recombinant human thrombin (rhThrombin) to bovine-derived thrombin and is designed to support broad product labeling for the use of rhThrombin as
The study will compare the efficacy of recombinant human thrombin (rhThrombin) to bovine-derived thrombin and is designed to support broad product labeling for the use of rhThrombin as
Keppra (levetiracetam) is currently approved for adjunctive therapy in the treatment of partial onset seizures in adults and children aged four years of age and older with epilepsy.
The license and development agreement covers NicOx’s phase IIa compound, NCX 1020, for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory disorders. Topigen has secured
The multi-center, placebo-controlled, phase IIa trial is designed to assess the safety, tolerability and efficacy of XP19986 in patients with gastroesophageal reflux disease (GERD). The clinical trial is
Ovide (malathion) is a prescription product for control of head lice in pediatric and adult populations. It is currently marketed by the US branch of Taro under the
The terms of the contract awarded by the Centers for Disease Control and Prevention (CDC), a unit of the US Department of Health and Human Services, were not
MedicAlert is making the Signature Genetics drug reaction test available to its members across the US with the help of Seryx. Terms of the agreement were not disclosed.
BLX-883 is the first clinical-stage therapeutic candidate produced in Biolex’ GMP facilities using its proprietary LEX system. In the phase I study BLX-883 was safely administered at a
The ongoing research is comparing the relative protection conveyed by Roche’s Tamiflu (oseltamivir) and Hemispherx’s Ampligen (dsRNA), alone and in combination, against the avian flu virus (H5N1). True
BAY 59-7939 (Factor Xa inhibitor) is currently undergoing phase II clinical trials. Phase III clinical trials to assess its effectiveness in the prevention of venous thromboembolism will also